For important risk and disclaimer information, Click here.
For additional information, please contact:
 |
Tamara Williams | Managing Director
|
 |
|
 |
(385) 600-1871
|
|
|
Gary Levy | Managing Director |
|
|
|
|
|
(516) 457-0104 |
Overview
- Investor returns expected via asset monetization (licensing, JV, M&A) or security trading in private/public markets
- Focused on high-burden conditions with limited or no effective pharmacotherapies
- Differentiation supported by peer-reviewed science, human tissue/clinical data, and a portfolio spanning AMPAkines, GABAkines, and a proprietary dronabinol formulation
- Non-dilutive support (grants, Australian R&D incentives) helps offset development risk and capital intensity
- Human safety and efficacy established for Ampakines (CX717, CX1739) and Dronabinol, enabling further Phase II/III clinical development
- Scientific validation includes several animal models in SCI and epilepsy
- Team includes experienced biotech founders, ex-Lilly leaders, and seasoned CNS drug developers
Path to Value Creation and Monetization
- Strategy: RespireRx monetizes programs via licensing, JVs, asset sales, or M&A rather than direct commercialization; value increases as assets advance through preclinical and clinical milestones
- Partner Economics: Typical structures include upfront payments, milestone payments, and royalties (or profit share in JVs), with development costs borne or shared by partners
- ResolutionRx: Late-stage proprietary dronabinol formulation for obstructive sleep apnea (large unmet need); pursuing 505(b)(2) pathway; plan to out-license/JV/sell
- EndeavourRx – AMPAkines:
- CX1739 – Mid-stage for spinal cord injury (bladder function); DoD-funded Phase 2A/B via trial at Shirley Ryan AbilityLab (~$1.8M grant)
- CX717 – Phase 2B for ADHD; ~$3M NIH grant pending or investor funding
- EndeavourRx – GABAkines: Preclinical program for treatment-resistant epilepsy; ~$3M NIH grant awarded; Phase 1 safety studies planned
Management
Dr. Arnold S. Lippa
Executive Chairman, CEO, CSO
- Founder and CEO of DOV Pharmaceuticals (IPO in 2002)
- 50+ years in neuropharma R&D and venture creation
- Inventor on numerous patents, author of peer-reviewed publications
- A prolific inventor with numerous patents in the medical arena and an author or co-author of numerous peer-reviewed scientific publications
Jeff E. Margolis
SVP, CFO, Board Member
- Founder of Aurora Capital LLC (former FINRA-registered firm)
- 30+ years in biotech capital markets
- Co-founder of life sciences investment entity with Dr. Lippa
Richard Purcell
SVP R&D
- 40 years of clinical development and commercialization experience
- Former EVP of NuGenerex Immuno-Oncology
- Active advisor and professor; led biotech/MedTech startups and M&A strategy
Senior Research Fellows
Dr. Jeffrey Witkin
Ex-Lilly; >250 publications; co-founder Gilgamesh Pharma; lead on GABAkines
Dr. Rok Cerne
30+ years CNS R&D; key role in analgesic/antiepileptic drug discovery; principal instigator on GABAkines grant application
Specific Risks
- Regulatory & Clinical Risk: Early-stage programs; no guarantees of success
- Capital Risk: History of operating losses; RespireRx Inc. lacks sufficient authorized common shares (may use preferred or require shareholder vote)
- Execution Risk: Dependent on CROs, strategic vendors, license holders
- Strategic Partnering Risk: Partnerships may not materialize or may be on unfavorable terms
- Macro Risk: Market volatility and public sector budget cuts (NIH, DOD) could reduce grant availability
- Competition: Competing with better-funded peers for IP, talent, capital, and market share
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
0 Comments
